Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-3BP-227 in NTSR1-positive solid tumors
NCT03525392Phase 1Terminated
- Sponsor
- Ipsen
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of zalsenertant tetraxetan lutetium Lu-177 in pancreatic ductal adenocarcinoma (PDAC), colorectal adenocarcinoma, gastric adenocarcinoma and 3 more, sponsored by Ipsen. Primary endpoint: Number of Participants With Dose-Limiting Toxicities at 16 weeks. Started May 2018; status: terminated.
02
Drugs
zalsenertant tetraxetan lutetium Lu-177
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal adenocarcinomagastric adenocarcinomagastrointestinal stromal tumor (GIST)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03525392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525392.